{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:35:24Z","timestamp":1791326124995,"version":"4.3.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,19]],"date-time":"2016-11-19T00:00:00Z","timestamp":1479513600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"crossref","award":["PROSUP (proc. # 1363443)"],"award-info":[{"award-number":["PROSUP (proc. # 1363443)"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006182","name":"FAPES","doi-asserted-by":"crossref","award":["(proc. # 0461\/2015)"],"award-info":[{"award-number":["(proc. # 0461\/2015)"]}],"id":[{"id":"10.13039\/501100006182","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00520-016-3486-6","type":"journal-article","created":{"date-parts":[[2016,11,19]],"date-time":"2016-11-19T04:16:23Z","timestamp":1479528983000},"page":"951-955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms"],"prefix":"10.1007","volume":"25","author":[{"given":"Silmara Mendes Martins","family":"Moulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico Jacob","family":"Eutr\u00f3pio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica de Oliveira","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda de Oliveira","family":"Busato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"Tadokoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,19]]},"reference":[{"key":"3486_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","volume":"105","author":"BJ Druker","year":"2000","unstructured":"Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3\u20137","journal-title":"J Clin Invest"},{"key":"3486_CR2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"3486_CR3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley GQ, Mes-Masson AM et al (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene. Science 233:212\u2013214","journal-title":"Science"},{"key":"3486_CR4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247:824\u2013830","journal-title":"Science"},{"key":"3486_CR5","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","volume":"87","author":"MA Kelliher","year":"1990","unstructured":"Kelliher MA, McLaughlin J, Witte ON, Rosenberg N (1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL. Proc Natl Acad Sci U S A 87:6649\u20136653","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3486_CR6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079\u20131082","journal-title":"Science"},{"key":"3486_CR7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561\u2013566","journal-title":"Nat Med"},{"key":"3486_CR8","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540\u20133546. doi: 10.1182\/blood-2007-03-080689","journal-title":"Blood"},{"key":"3486_CR9","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531\u20132541. doi: 10.1056\/NEJMoa055229","journal-title":"N Engl J Med"},{"key":"3486_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ajh.23180","volume":"87","author":"EJ Jabbour","year":"2012","unstructured":"Jabbour EJ, Kantarjian H, Eliasson L et al (2012) Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87:687\u2013691. doi: 10.1002\/ajh.23180","journal-title":"Am J Hematol"},{"key":"3486_CR11","unstructured":"WHO (2003) Adherence to long-term therapies"},{"key":"3486_CR12","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1053\/j.seminhematol.2009.01.010","volume":"46","author":"M O\u2019Dwyer","year":"2009","unstructured":"O\u2019Dwyer M, Atallah E (2009) Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Semin Hematol 46:S16\u2013S21","journal-title":"Semin Hematol"},{"key":"3486_CR13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","volume":"24","author":"DE Morisky","year":"1986","unstructured":"Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67\u201374","journal-title":"Med Care"},{"key":"3486_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0738-3991(98)00107-4","volume":"37","author":"BL Svarstad","year":"1999","unstructured":"Svarstad BL, Chewning BA, Sleath BL, Claesson C (1999) The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 37:113\u2013124","journal-title":"Patient Educ Couns"},{"key":"3486_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28\u201337. doi: 10.1182\/blood-2006-01-0092","journal-title":"Blood"},{"key":"3486_CR16","doi-asserted-by":"crossref","unstructured":"Baccarani M (2014) Molecular response in CML : where is the bar? Blood 124:469\u2013471","DOI":"10.1182\/blood-2014-06-578617"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3486-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3486-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3486-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:01:05Z","timestamp":1498348865000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3486-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,19]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3486"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3486-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,19]]}}}